Polytheragene, located at Evry (91, France), develops a specific know-how in the synthesis of polymers in general and more specifically of cationic polymers for gene therapy. Polytheragene is aiming to bring answers to the main problems linked with the non viral gene transfer techniques, such as the low efficiency of DNA transfer, and yield of the produced protein.
Polytheragene is developing polymer based technologies, especially formulated for bioproduction companies, biotechnology platforms, and research academic or corporate laboratories. Gene transfer is carried out using mixtures of the nucleic acid of interest with the appropriated synthetic vector. The resulting mixture allows transfection of target cells or tissues. Polytheragene commercializes PTG1 and PTG3 for transfection of various cell types with reduced toxicity.
Polytheragene is also developing PTG2 vectors for the transfection of skeletal muscles and the solubilization and vectorization of hydrophobic molecules.